Royal Bank Of Canada began coverage on shares of AveXis, Inc. (NASDAQ:AVXS) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage issued a sector perform rating and a $92.00 price objective on the stock.
A number of other research analysts have also recently commented on the company. Nomura initiated coverage on AveXis in a research note on Monday, August 28th. They set a reduce rating and a $52.00 price target on the stock. Zacks Investment Research upgraded AveXis from a sell rating to a hold rating in a research note on Thursday, September 7th. Jefferies Group LLC restated a buy rating and set a $108.00 price target (up from $92.00) on shares of AveXis in a research note on Friday, August 11th. BMO Capital Markets restated an outperform rating and set a $95.00 price target on shares of AveXis in a research note on Friday, June 16th. Finally, Morgan Stanley restated an overweight rating and set a $118.00 price target on shares of AveXis in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company. AveXis currently has an average rating of Buy and a consensus target price of $99.29.
Shares of AveXis (AVXS) opened at 88.08 on Thursday. The company’s market capitalization is $2.81 billion. AveXis has a 12 month low of $38.46 and a 12 month high of $99.45. The firm’s 50-day moving average price is $93.12 and its 200-day moving average price is $80.06.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same period in the prior year, the firm posted ($0.68) earnings per share. Equities research analysts expect that AveXis will post ($6.04) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “AveXis, Inc. (AVXS) Research Coverage Started at Royal Bank Of Canada” was reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.equitiesfocus.com/2017/09/17/avexis-inc-avxs-research-coverage-started-at-royal-bank-of-canada.html.
In other news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $91.52, for a total value of $162,905.60. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $162,905.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 5,340 shares of company stock worth $474,637. Insiders own 18.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in AVXS. Botty Investors LLC acquired a new stake in AveXis in the second quarter valued at $123,000. Quantbot Technologies LP acquired a new stake in AveXis in the first quarter valued at $117,000. Ameritas Investment Partners Inc. raised its stake in AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after buying an additional 1,622 shares in the last quarter. Seven Bridges Advisors LLC raised its stake in AveXis by 49.4% in the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock valued at $210,000 after buying an additional 846 shares in the last quarter. Finally, Amalgamated Bank acquired a new stake in AveXis in the second quarter valued at $219,000. Institutional investors and hedge funds own 94.71% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.